SCHEMBL1635529

SCHEMBL1635529

COc1cc(OC)c(C=CS(=O)(=O)Nc2ccc(OC)c(OC(=O)CN3CCN(C)CC3)c2)c(OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.45
USP2 O75604 1/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 2/20 0.38
PLK1 P53350 3/20 0.38
PTGS1 P23219 1/20 0.38
PTGS2 P35354 1/20 0.38
MET P08581 1/20 0.38
NQO2 P16083 1/20 0.38
FECH P22830 1/20 0.38
CLK3 P49761 1/20 0.38
HDAC3 O15379 1/20 0.37
HDAC4 P56524 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC7 Q8WUI4 1/20 0.37
HDAC2 Q92769 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1635527 1.00 ALDH1A1 (0.45) ALDH1A1USP2GAATSHRSMN1; SMN2
SCHEMBL2210194 0.85 KMT2A (0.52) ALDH1A1USP2GAATSHRSMN1; SMN2
SCHEMBL2210208 0.85 KMT2A (0.52) ALDH1A1USP2GAATSHRSMN1; SMN2
SCHEMBL1635039 0.85 PLK1 (0.43) ALDH1A1SMN1; SMN2KMT2APLK1MET
SCHEMBL1635037 0.85 PLK1 (0.43) ALDH1A1SMN1; SMN2KMT2APLK1MET
SCHEMBL1635211 0.84 ALDH1A1 (0.50) ALDH1A1USP2GAATSHRSMN1; SMN2
SCHEMBL1634102 0.83 PLK1 (0.43) ALDH1A1SMN1; SMN2KDM4EPLK1MET
SCHEMBL1635200 0.83 PLK1 (0.47) ALDH1A1SMN1; SMN2PLK1METNQO2
SCHEMBL1635238 0.83 PLK1 (0.42) ALDH1A1SMN1; SMN2MEN1KMT2APLK1
SCHEMBL1635203 0.83 PLK1 (0.47) ALDH1A1SMN1; SMN2PLK1METNQO2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3138832-A1 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS Temple University - Of The Commonwealth System of Higher Education (US) 2017-03-08 EP claimed
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-03-06 US claimed
EP-3138832-A1 SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS Temple University - Of The Commonwealth System of Higher Education (US) 2017-03-08 EP disclosed
US-7932242-B2 Anticancer agents; radiation and chemical resistance TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2011-04-26 US disclosed
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2008-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080058290-A1 Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders PCNA, MKI67, TP53 ALDH1A1 564/4885USP2 3549/4885GAA 1363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.